About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Translational Neuroscience Optimization of GlyT1 Inhibitor

NCT01911676·2 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Yale University

With

National Center for Advancing Translational Sciences (NCATS)

Age

21–65

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

1\) Males or females 21 to 65 years of age (inclusive).
2\) Diagnosis of Schizophrenia or Schizoaffective Disorder
3\) Able to provide written informed consent.
4\) Only CYP2D6 extensive metabolizers.

You may not be if

1\) No ongoing acute medical issues
2\) Clinically significant ECG abnormality
3\) Blood donation within eight weeks of the start of the study
4\) Current treatment with Clozapine

The record

StatusCompleted

PhasePhase 2

Taking part71

StartedAug 2013

UpdatedAug 19, 2024

Conditions

Cognitive Impairments Associated With Schizophrenia

Where2

Connecticut Mental Health Center
New Haven, Connecticut, United States
VA Connecticut Healthcare System
West Haven, Connecticut, United States

Clareo Health | Translational Neuroscience Optimization of GlyT1 Inhibitor